Log in

NASDAQ:ACOR - Acorda Therapeutics Stock Price, Forecast & News

$1.04
-0.07 (-6.31 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$1.04
Now: $1.04
$1.17
50-Day Range
$0.78
MA: $1.35
$2.09
52-Week Range
$0.70
Now: $1.04
$13.53
Volume903,676 shs
Average Volume1.28 million shs
Market Capitalization$49.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Read More
Acorda Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$192.41 million
Cash Flow$4.52 per share
Book Value$6.47 per share

Profitability

Net Income$-272,970,000.00
Net Margins-141.87%

Miscellaneous

Employees474
Market Cap$49.92 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.


Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

How has Acorda Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Acorda Therapeutics' stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACOR shares have increased by 3.0% and is now trading at $1.04. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Acorda Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acorda Therapeutics.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Acorda Therapeutics.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) released its earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.25. The biopharmaceutical company earned $50.50 million during the quarter, compared to analysts' expectations of $45.13 million. Acorda Therapeutics had a negative net margin of 141.87% and a negative return on equity of 22.18%. View Acorda Therapeutics' earnings history.

What guidance has Acorda Therapeutics issued on next quarter's earnings?

Acorda Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $130-160 million, compared to the consensus revenue estimate of $149.21 million.

What price target have analysts set for ACOR?

6 brokerages have issued 1 year price objectives for Acorda Therapeutics' stock. Their forecasts range from $1.40 to $12.00. On average, they anticipate Acorda Therapeutics' share price to reach $7.23 in the next year. This suggests a possible upside of 595.5% from the stock's current price. View analysts' price targets for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:
  • 1. Stifel Nicolaus analysts commented, "Stifel analyst Paul Matteis lowered the price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) to $7.00 (from $12.00) while maintaining a Hold rating." (8/2/2019)
  • 2. According to Zacks Investment Research, "Acorda got a huge boost with the approval of Inbrija in the United States, slightly before the scheduled time period. The drug is also under review in the EU with a decision expected in 2019. Inbrija was launched in February and registered its first sales in the first quarter. Acorda is seeking collaborations on the ex-U.S. commercialization of Inbrija with potential partners both across Europe and Japan. However, its key multiple sclerosis drug Ampyra is facing a generic competition which is significantly hurting Acorda’s top-line. The company expects to see a persistent decline in Ampyra sales during the quarters ahead in 2019. Shares of Acorda have underperformed the industry in the year so far. Nonetheless, Acorda boasts a strong pipeline addressing a wide range of disorders. The restructuring initiative is also saving costs." (7/3/2019)

Has Acorda Therapeutics been receiving favorable news coverage?

Headlines about ACOR stock have been trending very positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acorda Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAcorda Therapeutics.

Who are some of Acorda Therapeutics' key competitors?

What other stocks do shareholders of Acorda Therapeutics own?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the following people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
  • Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
  • Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64)

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (9.76%), Renaissance Technologies LLC (8.03%), Partner Fund Management L.P. (3.94%), Acadian Asset Management LLC (3.88%), State Street Corp (3.06%) and AQR Capital Management LLC (2.85%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View institutional ownership trends for Acorda Therapeutics.

Which institutional investors are selling Acorda Therapeutics stock?

ACOR stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Jefferies Group LLC, Geode Capital Management LLC, Partner Investment Management L.P., Bank of New York Mellon Corp, Diamond Hill Capital Management Inc., Renaissance Technologies LLC, and Prudential Financial Inc.. Company insiders that have sold Acorda Therapeutics company stock in the last year include Jane Wasman, and Ron Cohen. View insider buying and selling activity for Acorda Therapeutics.

Which institutional investors are buying Acorda Therapeutics stock?

ACOR stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., AQR Capital Management LLC, Skandinaviska Enskilda Banken AB publ, Acadian Asset Management LLC, Norges Bank, Jacobs Levy Equity Management Inc., Strs Ohio, and Bank of America Corp DE. View insider buying and selling activity for Acorda Therapeutics.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $1.04.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $49.92 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe. View additional information about Acorda Therapeutics.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is http://www.acorda.com/.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.


MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  421 (Vote Outperform)
Underperform Votes:  533 (Vote Underperform)
Total Votes:  954
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel